Aarti Pharmalabs Fixes Feb 16 as Record Date for Interim Dividend
Aarti Pharmalabs declared an interim dividend of ₹1.5 per equity share for FY24-25. The record date for this dividend payment has been set as February 16, 2026.
The declaration of an interim dividend is a positive event for shareholders, likely to be received well by the market. However, the impact is considered medium as it's a routine event for many companies and the amount is not exceptionally large.
The announcement of an interim dividend is generally positive for shareholders as it signifies a distribution of profits.
Aarti Pharmalabs Limited has announced that the Board of Directors, in their meeting held on February 09, 2026, declared an Interim Dividend of ₹1.5/- per equity share (representing 30%) on shares with a face value of ₹5/- each for the Financial Year 2024-25.
As per Regulation 42(1)(a) of the SEBI (LODR) Regulations, 2015, the company has fixed Monday, February 16, 2026, as the Record Date for the purpose of payment of this Interim Dividend.
The company has informed the stock exchanges, BSE Ltd. and the National Stock Exchange of India Limited, about this decision.
What to do with a filing like this
Aarti Pharmalabs Limited filed this with the NSE as a statutory disclosure, categorised under dividend. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aarti Pharmalabs Limited. Read the original for the full detail.